Published in J Clin Invest on October 01, 2003
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer (POSYTIVE) | NCT01015625
TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell (2005) 3.75
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest (2005) 1.98
Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell (2012) 1.80
A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Res (2012) 1.70
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One (2010) 1.66
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis (2010) 1.64
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis (2008) 1.62
The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc (2007) 1.55
Proteome-wide profiling of the MCF10AT breast cancer progression model. PLoS One (2010) 1.52
Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene (2011) 1.48
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res (2008) 1.47
Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res (2010) 1.47
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One (2010) 1.44
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41
Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene (2011) 1.38
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem (2009) 1.37
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med (2012) 1.31
Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One (2010) 1.31
Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res (2008) 1.27
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res (2009) 1.24
ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. Am J Pathol (2006) 1.24
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res (2006) 1.23
TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol (2015) 1.23
Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res (2009) 1.22
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med (2005) 1.22
LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med (2010) 1.20
Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail (2009) 1.17
Supervillin reorganizes the actin cytoskeleton and increases invadopodial efficiency. Mol Biol Cell (2008) 1.15
Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res (2012) 1.14
Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res (2008) 1.10
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia (2011) 1.09
Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene (2006) 1.08
Real-time motion analysis reveals cell directionality as an indicator of breast cancer progression. PLoS One (2013) 1.08
TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis (2007) 1.08
Tgf-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol (2010) 1.07
Evaluating human cancer cell metastasis in zebrafish. BMC Cancer (2013) 1.06
Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. Clin Exp Metastasis (2008) 1.05
Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene (2005) 1.04
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene (2009) 1.02
An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther (2013) 1.00
Perspectives on tissue interactions in development and disease. Curr Mol Med (2010) 1.00
Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene (2012) 0.98
Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia (2010) 0.98
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol (2015) 0.96
Requirement of TCF7L2 for TGF-beta-dependent transcriptional activation of the TMEPAI gene. J Biol Chem (2010) 0.96
TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br J Cancer (2008) 0.95
Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. Dev Cell (2009) 0.95
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
Smad4-expression is decreased in breast cancer tissues: a retrospective study. BMC Cancer (2006) 0.94
PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J Cell Mol Med (2007) 0.93
CLIC4 regulates TGF-β-dependent myofibroblast differentiation to produce a cancer stroma. Oncogene (2013) 0.93
Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer (2008) 0.93
ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. Nat Cell Biol (2014) 0.92
Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget (2016) 0.92
Two faces of TGF-beta1 in breast cancer. Mediators Inflamm (2014) 0.92
Plasma TGF-beta1-related survival of postmenopausal metastatic breast cancer patients. Clin Exp Metastasis (2004) 0.92
A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci U S A (2008) 0.91
A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Reports (2014) 0.91
The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. J Biol Chem (2014) 0.91
BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β(3) expression. Cell Oncol (Dordr) (2011) 0.89
Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br J Cancer (2010) 0.88
A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med (2013) 0.88
Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol Endocrinol (2011) 0.88
Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß. PLoS One (2013) 0.87
Molecular mechanism of SLC5A8 inactivation in breast cancer. Mol Cell Biol (2013) 0.86
SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol (2013) 0.86
Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends? J Cardiovasc Transl Res (2012) 0.86
Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment. Oncogene (2015) 0.86
TGFbeta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res (2009) 0.84
Abrogation of TGFbeta signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells. Exp Cell Res (2007) 0.84
Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer. Biochem Biophys Res Commun (2015) 0.84
Casein kinase 2 regulates the mRNA-destabilizing activity of tristetraprolin. J Biol Chem (2011) 0.84
Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer. BMC Cancer (2014) 0.83
Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res (2015) 0.83
Production of gastrointestinal tumors in mice by modulating latent TGF-β1 activation. Cancer Res (2012) 0.83
Causes and consequences of nuclear envelope alterations in tumour progression. Eur J Cell Biol (2016) 0.83
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Res (2012) 0.83
HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. Sci Rep (2015) 0.83
Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer. Br J Cancer (2009) 0.82
PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer. PLoS One (2015) 0.82
Recent developments in breast-conserving surgery for breast cancer patients. Langenbecks Arch Surg (2008) 0.82
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Oncotarget (2016) 0.82
Tumourigenic effect of Schistosoma haematobium total antigen in mammalian cells. Int J Exp Pathol (2009) 0.82
Spheroid assay to measure TGF-β-induced invasion. J Vis Exp (2011) 0.81
MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Oncotarget (2016) 0.80
Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. J Hepatol (2015) 0.80
Spontaneous mesotheliomas in F344/N rats are characterized by dysregulation of cellular growth and immune function pathways. Toxicol Pathol (2013) 0.80
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res (2015) 0.80
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
Putting tumours in context. Nat Rev Cancer (2001) 12.37
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res (1990) 9.85
The microenvironment of the tumour-host interface. Nature (2001) 9.17
TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev (2002) 4.66
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 4.64
TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol (1998) 4.44
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat (2001) 3.77
TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell (1996) 3.73
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol (1996) 2.62
Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res (1992) 2.29
Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology (2000) 2.27
The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog (1999) 2.17
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol (1993) 2.16
Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog (1993) 1.84
Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer (1992) 1.80
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst (1999) 1.67
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene (1998) 1.43
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg (1995) 1.40
Loss of growth factor dependence and conversion of transforming growth factor-beta 1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res (1988) 1.40
Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene (2001) 1.33
Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res (2003) 1.32
Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res (1999) 1.24
Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol (2002) 1.18
Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther (2002) 1.15
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res (2001) 1.12
The role of Sp1 in the differential expression of transforming growth factor-beta receptor type II in human breast adenocarcinoma MCF-7 cells. J Biol Chem (2000) 0.93
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood (2002) 4.07
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol (2004) 2.47
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 2.19
Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun (2012) 1.90
Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res (2002) 1.71
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem (2003) 1.66
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One (2010) 1.66
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res (2005) 1.60
Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res (2003) 1.59
Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res (2004) 1.58
Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer (2007) 1.50
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Invest (2010) 1.32
Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One (2010) 1.31
A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J Virol (2003) 1.25
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res (2002) 1.24
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res (2009) 1.24
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res (2006) 1.23
Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res (2009) 1.22
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res (2007) 1.22
Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp Med (2003) 1.22
Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res (2008) 1.21
Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat (2009) 1.20
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia (2009) 1.15
Protein pI shifts due to posttranslational modifications in the separation and characterization of proteins. Anal Chem (2005) 1.14
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer. Neoplasia (2011) 1.11
Visualization and identification of IL-7 producing cells in reporter mice. PLoS One (2009) 1.11
Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res (2008) 1.10
Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res (2004) 1.10
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis (2002) 1.10
A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol Cell Biol (2013) 1.10
Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther (2008) 1.08
An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hematol (2004) 1.08
Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). Oncogene (2004) 1.08
Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther (2009) 1.07
Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun (2012) 1.05
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res (2002) 1.03
Persistent mammary hyperplasia in FVB/N mice. Comp Med (2003) 1.03
A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics (2004) 1.02
Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression. Int J Cancer (2009) 1.02
Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling. Cancer Res (2011) 1.02
Structure-activity relationships OF N-methylthiolated beta-lactam antibiotics with C3 substitutions and their selective induction of apoptosis in human cancer cells. Front Biosci (2005) 0.99
Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis. J Biol Chem (2011) 0.98
Dysadherin: a new player in cancer progression. Cancer Lett (2007) 0.98
Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol (2009) 0.97
Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis. Biol Blood Marrow Transplant (2004) 0.95
Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab (2006) 0.93
Smad3 in the mammary epithelium has a nonredundant role in the induction of apoptosis, but not in the regulation of proliferation or differentiation by transforming growth factor-beta. Cell Growth Differ (2002) 0.93
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer (2008) 0.93
A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland. Breast Cancer Res (2010) 0.93
TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunol Immunother (2009) 0.91
Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood (2009) 0.91
Proteomic analysis of estrogen response of premalignant human breast cells using a 2-D liquid separation/mass mapping technique. Proteomics (2006) 0.90
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. Breast Cancer Res Treat (2009) 0.90
Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα. Proc Natl Acad Sci U S A (2013) 0.90
Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody. Free Radic Biol Med (2013) 0.90
Expression of POTE protein in human testis detected by novel monoclonal antibodies. Biochem Biophys Res Commun (2007) 0.89
Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett (2009) 0.89
GalNAcalpha1-3Gal, a new prognostic marker for cervical cancer. Int J Cancer (2010) 0.89
Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. Mol Cancer Res (2012) 0.89
Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One (2012) 0.89
Precancer in mice: animal models used to understand, prevent, and treat human precancers. Toxicol Pathol (2006) 0.88
Factors associated with different cigarette access behaviours among underage smoking youth who usually smoke contraband (native) cigarettes. Can J Public Health (2011) 0.88
Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia (2008) 0.88
Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. Biol Blood Marrow Transplant (2002) 0.88
TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res (2012) 0.87
Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses. Breast Cancer Res Treat (2006) 0.87
High sequence coverage of proteins isolated from liquid separations of breast cancer cells using capillary electrophoresis-time-of-flight MS and MALDI-TOF MS mapping. Anal Chem (2003) 0.86
Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments. PLoS One (2013) 0.86
Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors. Carcinogenesis (2006) 0.86
Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med (2002) 0.85
The antioxidant tempol reduces carcinogenesis and enhances survival in mice when administered after nonlethal total body radiation. Cancer Res (2012) 0.85
Profiling the progression of cancer: separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis. Proteomics (2003) 0.84
Identification of low molecular weight proteins isolated by 2-D liquid separations. J Mass Spectrom (2004) 0.83
Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta. Immune Netw (2009) 0.82
New allergies after cord blood transplantation. Cytotherapy (2013) 0.82
Monolithic column HPLC separation of intact proteins analyzed by LC-MALDI using on-plate digestion: An approach to integrate protein separation and identification. Anal Chem (2006) 0.82
Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects. PLoS One (2013) 0.82
Selenium and selenoprotein deficiencies induce widespread pyogranuloma formation in mice, while high levels of dietary selenium decrease liver tumor size driven by TGFα. PLoS One (2013) 0.81
Sunscreen prevention of melanoma in man and mouse. Pigment Cell Melanoma Res (2010) 0.81
Pillars Article: production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986. 163: 1037-1050. J Immunol (2014) 0.79
An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer. Breast Cancer Res (2014) 0.79